Jynarque, Samsca, Jinarc (tolvaptan) is a small molecule pharmaceutical. Tolvaptan was first approved as Jynarque on 2009-05-19. It is used to treat hyponatremia in the USA. It has been approved in Europe to treat autosomal dominant polycystic kidney and inappropriate adh syndrome. The pharmaceutical is active against vasopressin V2 receptor. In addition, it is known to target vasopressin V1a receptor. Samsca's patent is valid until 2030-04-07 (FDA).
|Trade Name||Jinarc, Samsca|
|Indication||autosomal dominant polycystic kidney, hyponatremia, inappropriate adh syndrome|
|Drug Class||Vasopressin receptor antagonists|